MA27700A1 - Vaccin contre l'hepatite c - Google Patents

Vaccin contre l'hepatite c

Info

Publication number
MA27700A1
MA27700A1 MA28285A MA28285A MA27700A1 MA 27700 A1 MA27700 A1 MA 27700A1 MA 28285 A MA28285 A MA 28285A MA 28285 A MA28285 A MA 28285A MA 27700 A1 MA27700 A1 MA 27700A1
Authority
MA
Morocco
Prior art keywords
hcv
expression
protein
polynucleotide sequence
core protein
Prior art date
Application number
MA28285A
Other languages
English (en)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27700A1 publication Critical patent/MA27700A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des procédés et à des compositions servant à traiter et à prévenir l'infection par le virus de l'hépatite C (VHC), ainsi que les symptômes et les maladies qui lui sont associés. L'invention concerne en particulier des vaccins à ADN qui codent la protéine du noyau du VHC, et une séquence polynucléotidique qui code au moins une autre protéine du VHC. Lesdits vaccins provoquent l'expression des protéines contenues dans la même cellule, et la séquence de la séquence polynucléotidique codant la protéine du noyau a fait l'objet d'une mutation, ou a été positionnée par rapport à la séquence polynucléotidique codant la ou les autres protéines du VHC, de façon que soit réduit l'effet négatif de l'expression de la protéine du noyau sur l'expression de la ou les autres protéines du VHC.
MA28285A 2002-11-15 2005-05-16 Vaccin contre l'hepatite c MA27700A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
MA27700A1 true MA27700A1 (fr) 2006-01-02

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28285A MA27700A1 (fr) 2002-11-15 2005-05-16 Vaccin contre l'hepatite c
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc

Country Status (21)

Country Link
US (4) US20060135451A1 (fr)
EP (2) EP1560845A1 (fr)
JP (2) JP2006518331A (fr)
KR (2) KR20050085010A (fr)
CN (2) CN1738833A (fr)
AR (1) AR041964A1 (fr)
AU (2) AU2003288084A1 (fr)
BR (2) BR0316244A (fr)
CA (2) CA2504654A1 (fr)
CO (1) CO5700833A2 (fr)
GB (1) GB0226722D0 (fr)
IS (2) IS7831A (fr)
MA (2) MA27700A1 (fr)
MX (2) MXPA05005202A (fr)
NO (2) NO20052136L (fr)
NZ (2) NZ539998A (fr)
PL (2) PL376882A1 (fr)
RU (2) RU2363492C2 (fr)
TW (1) TW200502246A (fr)
WO (2) WO2004046176A1 (fr)
ZA (2) ZA200503802B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (fr) * 2004-10-18 2014-01-08 Globeimmune, Inc. Moyens thérapeutiques à base de levure contre l'infection par hépatite C chronique
US8178086B2 (en) * 2006-01-04 2012-05-15 Novartis Vaccines And Diagnostics, Inc. Activation of HCV specific T cells
MX2008011361A (es) * 2006-03-09 2008-09-15 Transgene Sa Proteina de fusion no-estructural del virus de hepatitis c.
CA2657955A1 (fr) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Particules de type virus chimerique
EP2044198A4 (fr) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc Particules de type virus grippal chimérique
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (fr) * 2008-04-22 2009-10-29 Rutgers, The State University Compositions de produit de construction e2 de vhc et procedes correspondants
WO2010011870A2 (fr) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions et procédés de traitement de l'hépatite c
WO2010033841A1 (fr) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunothérapie pour infection chronique par le virus de l'hépatite c
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
JP2016513115A (ja) * 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
CA2070952A1 (fr) * 1991-06-11 1992-12-12 Makoto Seki Gene du virus de l'hepatite c ou fragment dudit gene, polypeptide code par le gene
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
HUT77870A (hu) * 1994-10-05 1998-09-28 Apollon, Inc. Hepatitiszvírus elleni vakcinák
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
WO1997047358A1 (fr) * 1996-06-11 1997-12-18 Merck & Co., Inc. Genes synthetiques de l'hepatite c
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (fr) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Epitopes antigeniques et polypeptides de mosaique des proteines du virus de l'hepatite c
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
WO2001038360A2 (fr) * 1999-11-24 2001-05-31 Chiron Corporation Polypeptide non structurel du virus de l'hepatite c
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
NZ539998A (en) 2008-04-30
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
GB0226722D0 (en) 2002-12-24
CO5700833A2 (es) 2006-11-30
CN1738833A (zh) 2006-02-22
ZA200503803B (en) 2006-08-30
MXPA05005202A (es) 2006-01-27
CA2504715A1 (fr) 2004-06-03
WO2004046176A1 (fr) 2004-06-03
KR20050085010A (ko) 2005-08-29
AR041964A1 (es) 2005-06-01
US20090232847A1 (en) 2009-09-17
JP2006518331A (ja) 2006-08-10
US20090104231A1 (en) 2009-04-23
NO20052149D0 (no) 2005-05-02
BR0316291A (pt) 2005-10-11
ZA200503802B (en) 2006-08-30
AU2003288084A1 (en) 2004-06-15
IS7831A (is) 2005-04-28
PL376882A1 (pl) 2006-01-09
NZ539999A (en) 2008-03-28
KR20050085009A (ko) 2005-08-29
EP1560845A1 (fr) 2005-08-10
US20060246090A1 (en) 2006-11-02
NO20052136D0 (no) 2005-05-02
AU2003288072A1 (en) 2004-06-15
TW200502246A (en) 2005-01-16
RU2323744C2 (ru) 2008-05-10
IS7830A (is) 2005-04-28
CA2504654A1 (fr) 2004-06-03
NO20052136L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26
NO20052149L (no) 2005-07-11
EP1560844A1 (fr) 2005-08-10
MA27699A1 (fr) 2006-01-02
CN1738834A (zh) 2006-02-22
MXPA05005203A (es) 2006-01-27
PL376967A1 (pl) 2006-01-23
WO2004046175A1 (fr) 2004-06-03
US20060135451A1 (en) 2006-06-22
RU2005113692A (ru) 2006-01-27
RU2005113691A (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
MA27700A1 (fr) Vaccin contre l'hepatite c
CY1113650T1 (el) Συντηρημενα αντιγονα neisseria
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
EE200200510A (et) POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks
CA2505942A1 (fr) Vaccin contre le virus du nil occidental
WO2002086100A3 (fr) Expression, dans la levure, de proteines de l'enveloppe du virus de l'hepatite c (vhc) a nucleo-glycosylation
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
JP2004236637A5 (fr)
ATE495247T1 (de) Chromoprotein und fluoroproteine
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
DE60231057D1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
TW200509964A (en) VP1 of foot-and-mouth disease virus
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
IL75553A0 (en) Ache like peptide
Tokutake Complete separation of the triplet components of neurofilament by DE-52 column chromatography depends upon urea concentration
DE60027581D1 (de) Design von immunogene
NO20051840L (no) IHNV G-protein til immunstimulering.
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ITMI20001985A1 (it) Varianti dell'allergene maggiore par j 2 di parietaria judaica
DK1539808T3 (da) GM-negativ EHV-mutanter uden heterologe elementer